LeMaitre Vascular, Inc.
LMATHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeLeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. At a $1.82B market cap, LeMaitre Vascular, Inc. ranks as a small-cap company within healthcare. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services.
Market Cap
$1.82B
Beta
0.49
P/E (TTM)
27.83
P/E (Fwd)
25.04
EPS (TTM)
$2.86
EPS (Fwd)
$3.18
ROE
16.8%
ROA
7.4%
Cash
$376.2M
Total Debt
$190.3M
Free CF
$49.3M
52W Change
-12.9%
Annual Financials
Cash vs Debt
Where LMAT stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, LMAT finished 17.37% below its 150-day moving average ($98.12) and 14.26% below its 200-day moving average ($94.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LMAT overbought or oversold?
At the September 2, 2026 close, LMAT's RSI(14) was 46.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $376.2M in cash and $190.3M in debt, LMAT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $49.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 16.8% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $161.7M (2022) to $249.6M (2025), reflecting a 54% increase over the period.
The relatively low beta of 0.49 suggests LMAT is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence LeMaitre Vascular, Inc.'s trajectory.